RecruitingNCT05247502

Impact of the Characteristics of Acute Renal Failure in Intensive Care on the Long-term Renal Prognosis: Prospective Multicenter Cohort Study


Sponsor

University Hospital, Clermont-Ferrand

Enrollment

860 participants

Start Date

Nov 22, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to assess the impact of Acute Kidney Injury (AKI) characteristics on long-term renal prognosis in Intensive Care Unit (ICU) patients.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking patients who develop acute kidney injury (sudden kidney damage) while in the intensive care unit (ICU) to understand how their kidneys recover — or don't — in the long term. Researchers want to identify which features of ICU-related kidney injury predict lasting kidney problems. **You may be eligible if...** - You are 18 or older - You are hospitalized in an ICU for more than 24 hours **You may NOT be eligible if...** - You are under 18 years old - You are pregnant - You were already on dialysis before your ICU admission - You were admitted to the ICU for a kidney transplant - You are under court-ordered legal protection - You refuse to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALData observation

At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.


Locations(2)

Centre Jean-Perrin

Clermont-Ferrand, France

CHU clermont-ferrand

Clermont-Ferrand, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05247502


Related Trials